Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Zynerba Pharmaceuticals, Inc. (ZYNE) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Zynerba Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1621443.
Total stock buying since 2015: $2,383,737.
Total stock sales since 2015: $185,310.
Total stock option exercises since 2015: $63,508.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 142,554 | $119,940 | 0 | $0 |
| 2022 | 0 | $0 | 30,735 | $33,781 | 0 | $0 |
| 2018 | 82,003 | $722,571 | 0 | $0 | 0 | $0 |
| 2017 | 110,200 | $1,175,336 | 0 | $0 | 0 | $0 |
| 2016 | 17,000 | $257,070 | 3,000 | $31,589 | 0 | $0 |
| 2015 | 15,500 | $228,760 | 0 | $0 | 15,957 | $63,508 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-09 | 0 | $0 | 48,145 | $63,837 | 0 | $0 |
| 2023-06 | 0 | $0 | 690 | $240 | 0 | $0 |
| 2023-02 | 0 | $0 | 3,173 | $1,719 | 0 | $0 |
| 2023-01 | 0 | $0 | 90,546 | $54,144 | 0 | $0 |
| 2022-07 | 0 | $0 | 30,482 | $33,528 | 0 | $0 |
| 2022-06 | 0 | $0 | 253 | $253 | 0 | $0 |
| 2018-08 | 36,118 | $216,488 | 0 | $0 | 0 | $0 |
| 2018-05 | 20,885 | $218,443 | 0 | $0 | 0 | $0 |
| 2018-03 | 10,000 | $92,790 | 0 | $0 | 0 | $0 |
| 2018-01 | 15,000 | $194,850 | 0 | $0 | 0 | $0 |
| 2017-10 | 100,000 | $973,757 | 0 | $0 | 0 | $0 |
| 2017-05 | 10,200 | $201,579 | 0 | $0 | 0 | $0 |
| 2016-12 | 17,000 | $257,070 | 0 | $0 | 0 | $0 |
| 2016-08 | 0 | $0 | 3,000 | $31,589 | 0 | $0 |
| 2015-09 | 0 | $0 | 0 | $0 | 15,957 | $63,508 |
| 2015-08 | 15,500 | $228,760 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-09-13 | Jones Kenneth T (See Remarks) | Sale | 2,505 | 1.33 | 3,321 |
| 2023-09-13 | Rosenberger Brian (VP, Commercial & Business Dev.) | Sale | 6,411 | 1.33 | 8,500 |
| 2023-09-13 | Fickenscher James E (Chief Financial Officer) | Sale | 8,998 | 1.33 | 11,931 |
| 2023-09-13 | Sebree Terri B (President) | Sale | 12,401 | 1.33 | 16,443 |
| 2023-09-13 | Anido Armando (Chairman & Chief Exec. Officer) | Sale | 17,830 | 1.33 | 23,642 |
| 2023-06-14 | Stephenson Pamela (Director) | Sale | 115 | .35 | 40 |
| 2023-06-14 | Butler John P. (Director) | Sale | 115 | .35 | 40 |
| 2023-06-14 | Federici William J (Director) | Sale | 115 | .35 | 40 |
| 2023-06-14 | Cooper Warren D (Director) | Sale | 115 | .35 | 40 |
| 2023-06-14 | Kisner Daniel L (Director) | Sale | 115 | .35 | 40 |
| 2023-06-14 | Moch Kenneth I (Director) | Sale | 115 | .35 | 40 |
| 2023-02-15 | Parker Albert P (Chief Legal Officer) | Sale | 3,173 | .54 | 1,719 |
| 2023-01-23 | Rosenberger Brian (VP, Commercial & Business Dev.) | Sale | 12,663 | .60 | 7,572 |
| 2023-01-23 | Fickenscher James E (Chief Financial Officer) | Sale | 17,769 | .60 | 10,625 |
| 2023-01-23 | Sebree Terri B (President) | Sale | 24,661 | .60 | 14,747 |
| 2023-01-23 | Anido Armando (Chairman & Chief Exec. Officer) | Sale | 35,453 | .60 | 21,200 |
| 2022-07-19 | Rosenberger Brian (VP, Commercial & Business Dev.) | Sale | 4,289 | 1.10 | 4,717 |
| 2022-07-19 | Fickenscher James E (Chief Financial Officer) | Sale | 6,013 | 1.10 | 6,614 |
| 2022-07-19 | Sebree Terri B (President) | Sale | 8,281 | 1.10 | 9,109 |
| 2022-07-19 | Anido Armando (Chairman & CEO) | Sale | 11,899 | 1.10 | 13,088 |
| 2022-06-14 | Stephenson Pamela (Director) | Sale | 40 | 1.01 | 40 |
| 2022-06-14 | Butler John P. (Director) | Sale | 53 | 1.01 | 53 |
| 2022-06-14 | Federici William J (Director) | Sale | 40 | 1.01 | 40 |
| 2022-06-14 | Cooper Warren D (Director) | Sale | 40 | 1.01 | 40 |
| 2022-06-14 | Kisner Daniel L (Director) | Sale | 40 | 1.01 | 40 |
| 2022-06-14 | Moch Kenneth I (Director) | Sale | 40 | 1.01 | 40 |
| 2018-08-22 | Butler John P. (Director) | Buy | 5,000 | 6.43 | 32,155 |
| 2018-08-06 | Hanlon Suzanne M. (Sec, VP & General Counsel) | Buy | 3,800 | 5.80 | 22,047 |
| 2018-08-06 | Fickenscher James E (Chief Financial Officer) | Buy | 8,518 | 5.97 | 50,843 |
| 2018-08-06 | Sebree Terri B (President) | Buy | 3,800 | 5.79 | 22,013 |
| 2018-08-06 | Anido Armando (Chairman & Chief Exec. Officer) | Buy | 15,000 | 5.96 | 89,430 |
| 2018-05-30 | Rapp Michael | Buy | 5,885 | 10.45 | 61,498 |
| 2018-05-02 | Rapp Michael | Buy | 15,000 | 10.46 | 156,945 |
| 2018-03-22 | Rapp Michael | Buy | 10,000 | 9.28 | 92,790 |
| 2018-01-02 | Rapp Michael | Buy | 15,000 | 12.99 | 194,850 |
| 2017-10-23 | Rapp Michael | Buy | 25,745 | 9.94 | 255,802 |
| 2017-10-20 | Rapp Michael | Buy | 30,000 | 9.79 | 293,550 |
| 2017-10-19 | Rapp Michael | Buy | 44,255 | 9.59 | 424,405 |
| 2017-05-15 | Anido Armando (Chairman & Chief Exec. Officer) | Buy | 1,500 | 19.57 | 29,355 |
| 2017-05-12 | Fickenscher James E (Chief Financial Officer) | Buy | 5,200 | 19.82 | 103,064 |
| 2017-05-12 | Anido Armando (Chairman & Chief Exec. Officer) | Buy | 3,500 | 19.76 | 69,160 |
| 2016-12-29 | Rapp Michael | Buy | 10,000 | 15.85 | 158,500 |
| 2016-12-07 | Fickenscher James E (Chief Financial Officer) | Buy | 4,000 | 14.03 | 56,120 |
| 2016-12-06 | Fickenscher James E (Chief Financial Officer) | Buy | 3,000 | 14.15 | 42,450 |
| 2016-08-16 | Hanlon Suzanne M. (Sec, General Counsel & VP HR) | Sale | 3,000 | 10.53 | 31,589 |
| 2015-09-11 | Baron Richard A (Chief Financial Officer) | Option Ex | 15,957 | 3.98 | 63,508 |
| 2015-08-10 | Harrison Thomas L (Director) | Buy | 12,500 | 14.00 | 175,000 |
| 2015-08-05 | Hanlon Suzanne M. (Sec, General Counsel & VP HR) | Buy | 3,000 | 17.92 | 53,760 |
Insider trading activities including stock purchases, stock sales, and option exercises of ZYNE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Zynerba Pharmaceuticals, Inc. (symbol ZYNE, CIK number 1621443) see the Securities and Exchange Commission (SEC) website.